BofA lowered the firm’s price target on Denali Therapeutics (DNLI) to $26 from $27 and keeps a Buy rating on the shares. The firm made changes to its model following the company’s Q3 update, noting that Denali management highlighted that they continue to engage with the FDA on the ongoing biologics license application review of tividefusp alfa for Hunter syndrome following the recent extension with new target action date of April 5, 2026.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNLI:
- Denali Therapeutics price target lowered to $26 from $27 at BofA
- Denali Therapeutics: Promising Future with Tivi Approval and Unique Brain Shuttling Platform
- Denali Therapeutics: Strategic Positioning and Growth Potential with Pioneering TfR-Enabled Medicine Launch
- Denali Therapeutics Reports Increased Losses Amid Strategic Collaborations
- Denali Therapeutics: Promising Pipeline and Strategic Progress Justify Buy Rating